New allergy drug shows promise in early trial
NCT ID NCT03570957
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a single dose of the investigational drug MT-2990 in 75 adults with seasonal allergic rhinitis triggered by Japanese cedar pollen. The main goals were to check the drug's safety, how the body processes it, and whether it can reduce allergy symptoms when patients are exposed to pollen in a controlled chamber. Results will help decide if larger studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT-2990
What this could lead to
If successful, this could lead to a new treatment option for seasonal allergic rhinitis caused by Japanese cedar pollen.
What could go wrong
This is an early Phase 1 study with only 75 participants, so results may not confirm effectiveness or safety in larger populations. The drug may cause side effects or fail to provide meaningful symptom relief.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
Tokyo, Japan